Avicanna Inc. (AVCNF)
| Market Cap | 12.54M -46.8% |
| Revenue (ttm) | 18.51M +2.0% |
| Net Income | -2.24M |
| EPS | -0.02 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | 0.0970 |
| Previous Close | 0.0960 |
| Day's Range | 0.0950 - 0.0970 |
| 52-Week Range | 0.0684 - 0.2363 |
| Beta | 0.33 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 13, 2026 |
About Avicanna
Avicanna Inc., a commercial-stage biopharmaceutical company, engages in the research, development, advancement, and commercialization of evidence-based cannabinoid-based products and formulations for medical and pharmaceutical markets in Canada and internationally. It provides medical cannabis formulary products, including oral, sublingual, topical, and transdermal deliveries with various ratios of cannabinoids under the RHO Phyto brand; and indication-specific cannabinoid-based candidates to address unmet medical needs in the areas of dermatol... [Read more]
Financial Performance
In 2025, Avicanna's revenue was 25.48 million, an increase of 0.08% compared to the previous year's 25.46 million. Losses were -2.76 million, -39.75% less than in 2024.
Financial numbers in CAD Financial StatementsNews
Avicanna Introduces QUIX™ Rapid-Onset Medical Cannabis Portfolio
Initial Medical Cannabis SKUs, Including Rapid-Onset Capsules and Soft Chews, Planned for Q3 2026 Improving Patient Access with Accurately Dosed, Rapid-Onset and Non-Combustible Formats
Avicanna Announces Promotion of Nick Hilborn CPA CA to Chief Financial Officer
TORONTO, June 30, 2026 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or “Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing and commer...
Splash Beverage Group Invests in Avicanna, a Leading Cannabinoid Biopharmaceutical Platform, Advancing Its Transformation Into Cannabinoid Healthcare
FORT LAUDERDALE, Fla., June 15, 2026 (GLOBE NEWSWIRE) -- Splash Beverage Group, Inc. (NYSE American: SBEV) today announced the completion of a CDN$300,000 strategic investment in Avicanna Inc. (TSX: A...
Avicanna Announces Closing of Non-Brokered Private Placement
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF UNITED STATES SECURITIES LA...
Avicanna Earnings release: Q1 2026
Avicanna released its Q1 2026 earnings on May 14, 2026, summarizing the period's financial results.
Avicanna Reports Q1 2026 Financial Statements
Record revenue and gross profits driven by Canadian commercial growth and proprietary product expansion Continued advancement of pharmaceutical pipeline, medical affairs initiatives and international ...
Avicanna Announces Results of Annual General and Special Meeting
TORONTO, May 08, 2026 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or “Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing and commerc...
Avicanna Transcript: AGM 2026
The meeting confirmed strong financial improvements in 2025, including higher gross margins, reduced net loss, and positive adjusted EBITDA in Q4. All board nominees and proposals, including the incentive plan, were approved, and strategic focus remains on Canadian, U.S., and international expansion.
Avicanna announces McCormack tendered her resignation as member of board
Avicanna (AVCNF) announces that Eileen McCormack, who was not on the slate of directors for re-election or election as outlined in the circular at the upcoming annual general and special…
Avicanna Announces Change in Board of Directors
TORONTO, May 01, 2026 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing and com...
Avicanna Welcomes Initial U.S. Rescheduling of Medical Cannabis & Provides Scientific Update
Rescheduling aligns with Avicanna's established pharmaceutical and medical cannabis strategyRescheduling further supports advancement of R&D, clinical development, and medical affairs initiatives
Annual General and Special Meeting of Shareholders to be held May 7, 2026
TORONTO, April 21, 2026 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing and c...
Avicanna Earnings Call Transcript: Q4 2025
Revenue reached CAD 25.5 million with a 53% gross margin and near break-even adjusted EBITDA. Expanded to 24 international markets, launched new proprietary drug delivery technologies, and improved operational efficiency. Positioned for further growth and U.S. market entry in 2026.
Avicanna Earnings release: Q4 2025
Avicanna released its Q4 2025 earnings on April 7, 2026, summarizing the period's financial results.
Avicanna Announces Changes to its Board of Directors
TORONTO, April 06, 2026 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing and ...
Avicanna Reports Full Year 2025 Audited Financial Statements
Achieved positive adjusted EBITDA in Q4 2025 and near break-even $(0.29) million for the full year Advancements across business units, R&D, and clinical development to support scale and international ...
Avicanna Subsidiary SMGH Completes First Commercial Export to Australia
This marks the first commercial export of organic certified flower for SMGH The export represents the 21 st market for SMGH and 24 th market for all Avicanna products
Avicanna sponsors University of Calgary THC dose finding trial
Avicanna (AVCNF) announced the initiation of new Phase I randomized, double-blinded, placebo-controlled, dose-finding clinical trial led by researchers at the University of Calgary’s Cumming School of...
Avicanna Announces Sponsorship of University of Calgary THC Dose Finding Clinical Trial
New randomized controlled trial to evaluate dose-dependent effects of oral THC on anxiety and stress using Avicanna's proprietary capsules New randomized controlled trial to evaluate dose-dependent ef...
Avicanna Transcript: Life Sciences Virtual Investor Forum
The company is advancing a diversified, evidence-based cannabinoid platform with four business divisions, a robust pharmaceutical pipeline, and proprietary IP. It is expanding internationally, leveraging Canadian success, and expects U.S. regulatory changes to unlock new growth and partnerships.
Avicanna announces Medical Cannabis Real World Evidence results, publication
Avicanna (AVCNF) announced the publication of results from an investigator-led Medical Cannabis Real-World Evidence study conducted through the MyMedi.ca platform. The study led by Dr. Hance Clarke, D...
Avicanna Announces Medical Cannabis Real World Evidence Results and Publication
Prospective observational study reports improvements in pain-related outcomes, mental health measures, and quality of life among patients using physician-authorized medical cannabis in the Canadian Jo...
Avicanna director Paul Fornazzari resigns, Michael Kott appointed to board
Avicanna (AVCNF) announces Paul Fornazzari’s resignation from the Company’s board of directors and the appointment of Michael Kott to its board of directors. Kott, who will join the board January…
Avicanna ‘applauds’ executive order to reclassify cannabis
Avicanna (AVCNF) applauds President Trump’s executive order directing the reclassification of cannabis as a less dangerous substance from Schedule I to Schedule III controlled substance while also men...
Avicanna Applauds President Trump's Executive Order to Reclassify Cannabis & Provides Scientific Update
Avicanna's evidence-based pathway for cannabinoid-based medicine aligns with the executive order. Avicanna's 2025 advances across R&D, clinical development, and medical affairs.